{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:08:36Z","timestamp":1793621316088,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.pnpbp.2015.08.010","type":"journal-article","created":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T18:05:40Z","timestamp":1440525940000},"page":"34-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":174,"special_numbering":"C","title":["Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones"],"prefix":"10.1016","volume":"65","author":[{"given":"Felice","family":"Iasevoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Balletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Latte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Formato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Prinzivalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Tomasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"de Bartolomeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2015.08.010_bb0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0920-9964(93)90017-D","article-title":"A multidimensional (pharmacokinetic and clinical\u2013biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance","volume":"8","author":"Altamura","year":"1993","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10072-008-0866-9","article-title":"The brief assessment of cognition in schizophrenia. Normative data for the Italian population","volume":"29","author":"Anselmetti","year":"2008","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00023210-200418130-00004","article-title":"Impact of atypical antipsychotics on quality of life in patients with schizophrenia","volume":"18","author":"Awad","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/acps.12327","article-title":"The practical management of refractory schizophrenia \u2014 the Maudsley Treatment REview and Assessment Team service approach","volume":"130","author":"Beck","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0030","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jpsychires.2006.08.003","article-title":"Self-assessment of functional status in schizophrenia","volume":"41","author":"Bowie","year":"2007","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.biopsych.2007.05.022","article-title":"Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures","volume":"63","author":"Bowie","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0040","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1176\/appi.ajp.2012.11091337","article-title":"Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior","volume":"169","author":"Bowie","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.schres.2013.02.026","article-title":"Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia","volume":"146","author":"Burton","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0050","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","article-title":"Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case\u2013control study of risks versus benefits","volume":"161","author":"Centorrino","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0055","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2010.09.020","article-title":"A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia","volume":"125","author":"Couture","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psychres.2013.06.042","article-title":"Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses","volume":"210","author":"de Bartolomeis","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1192\/bjp.bp.112.118018","article-title":"Effect of psychosocial interventions on social functioning in depression and schizophrenia: meta-analysis","volume":"202","author":"De Silva","year":"2013","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0075","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0080","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0085","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/schbul\/sbl067","article-title":"Social\/communication skills, cognition, and vocational functioning in schizophrenia","volume":"33","author":"Dickinson","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/schbul\/sbp115","article-title":"The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements","volume":"36","author":"Dixon","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0095","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0269881109359097","article-title":"A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis","volume":"25","author":"Fallon","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0100","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/mp.2014.56","article-title":"Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients","volume":"20","author":"Frank","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/wps.20167","article-title":"The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia","volume":"13","author":"Galderisi","year":"2014","journal-title":"World Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00406-013-0463-7","article-title":"Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment","volume":"264","author":"Gilbert","year":"2014","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0120","first-page":"43","article-title":"Direct measurement of disability","volume":"6","author":"Harvey","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0125","first-page":"15","article-title":"International assessment of functional skills in people with schizophrenia","volume":"8","author":"Harvey","year":"2011","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0130","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/schbul\/sbm040","article-title":"Performance-based measures of functional skills: usefulness in clinical treatment studies","volume":"33","author":"Harvey","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0135","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1176\/appi.ajp.2009.09010106","article-title":"Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden","volume":"166","author":"Harvey","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0140","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/appi.ajp.2011.10121723","article-title":"Validating the measurement of real-world functional outcomes: phase I results of the VALERO study","volume":"168","author":"Harvey","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0145","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jpsychires.2012.08.018","article-title":"Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings","volume":"46","author":"Harvey","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0155","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2147\/NDT.S47571","article-title":"Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment","volume":"9","author":"Iasevoli","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0160","doi-asserted-by":"crossref","first-page":"762127","DOI":"10.1155\/2014\/762127","article-title":"Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study","volume":"2014","author":"Iasevoli","year":"2014","journal-title":"ISRN Pharmacol."},{"issue":"Suppl. 9","key":"10.1016\/j.pnpbp.2015.08.010_bb0165","first-page":"35","article-title":"Treatment-resistant schizophrenic patients","volume":"57","author":"Kane","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.psychres.2009.04.001","article-title":"Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment","volume":"178","author":"Kaneda","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.schres.2014.02.022","article-title":"A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis","volume":"155","author":"Kimura","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0185","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.146.3.229","article-title":"Schizophrenia with good and poor outcome. I: early clinical features, response to neuroleptics and signs of organic dysfunction","volume":"146","author":"Kolakowska","year":"1985","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1744-859X-9-24","article-title":"Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension","volume":"9","author":"Kozma","year":"2010","journal-title":"Ann. Gen. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.pnpbp.2015.08.010_bb0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/00023210-200418002-00002","article-title":"Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life","volume":"18","author":"Lambert","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/JCP.0000000000000310","article-title":"Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia","volume":"35","author":"Lee","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0205","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0210","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/schbul\/sbp044","article-title":"Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel","volume":"37","author":"Leifker","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200303000-00003","article-title":"High-dose olanzapine for treatment\u2013refractory schizophrenia","volume":"26","author":"Lerner","year":"2003","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0220","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0225","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1017\/S1355617708080600","article-title":"Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: a cross-sectional study","volume":"14","author":"Leung","year":"2008","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0230","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0893-133X(97)00045-6","article-title":"Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity","volume":"17","author":"Lieberman","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0235","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1004640408501","article-title":"Treatment refractory schizophrenia","volume":"71","author":"Lindenmayer","year":"2000","journal-title":"Psychiatry Q."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0240","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2045125314558054","article-title":"Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme","volume":"5","author":"Mace","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0245","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/schbul\/16.4.563","article-title":"Defining treatment refractoriness in schizophrenia","volume":"16","author":"Meltzer","year":"1990","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0250","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0255","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0140-6736(96)07495-8","article-title":"Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-244X-11-113","article-title":"Is the PANSS used correctly? A systematic review","volume":"11","author":"Obermeier","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0265","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1176\/ps.62.10.pss6210_1138","article-title":"Predicting psychiatric hospital admission among adults with schizophrenia","volume":"62","author":"Olfson","year":"2011","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0270","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1192\/bjp.bp.107.042895","article-title":"High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing","volume":"192","author":"Paton","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0275","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.schres.2004.07.014","article-title":"High-dose quetiapine in treatment refractory schizophrenia","volume":"73","author":"Pierre","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0280","doi-asserted-by":"crossref","first-page":"325052","DOI":"10.1155\/2014\/325052","article-title":"Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia","volume":"2014","author":"Quarantelli","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0285","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psychres.2014.04.018","article-title":"Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real world-setting","volume":"218","author":"Rocca","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1176\/appi.ajp.163.3.411","article-title":"Barriers to employment for people with schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0295","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1121189X00005182","article-title":"Subjective response to neuroleptic medication: a validation study of the Italian version of the Drug Attitude Inventory (DAI)","volume":"10","author":"Rossi","year":"2001","journal-title":"Epidemiol. Psichiatr. Soc."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0300","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s11136-005-7387-2","article-title":"Validity and reliability of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire","volume":"14","author":"Rossi","year":"2005","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0305","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hup.1067","article-title":"Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder","volume":"24","author":"Rossi","year":"2009","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0310","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.schres.2011.05.003","article-title":"Assessing everyday functioning in schizophrenia: not all informants seem equally informative","volume":"131","author":"Sabbag","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0315","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4088\/JCP.13m08817","article-title":"Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia spectrum and bipolar I disorders: the 24-month follow-up ACCESS II study","volume":"75","author":"Schottle","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0320","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0022-3956(97)00052-6","article-title":"The natural history and pathophysiology of treatment resistant schizophrenia","volume":"32","author":"Sheitman","year":"1998","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0325","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/0269881114541013","article-title":"Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review","volume":"29","author":"Sim","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0330","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0924-9338(99)00223-0","article-title":"Discriminant cognitive factors in responder and non-responder patients with schizophrenia","volume":"14","author":"Stip","year":"1999","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2015.08.010_bb0335","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.schres.2015.03.033","article-title":"Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity","volume":"165","author":"Strassnig","year":"2015","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2015.08.010_bb0340","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.psychres.2015.02.021","article-title":"Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia","volume":"227","author":"Suzuki","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0345","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/ajp.2007.164.3.428","article-title":"Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study","volume":"164","author":"Swartz","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0350","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/schbul\/sbq126","article-title":"Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia","volume":"38","author":"Szeszko","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0355","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/schbul\/sbr006","article-title":"Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis","volume":"38","author":"Tadokoro","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0360","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0269881115570083","article-title":"Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia","volume":"29","author":"Takase","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0365","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1176\/appi.ajp.159.12.2013","article-title":"Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis","volume":"159","author":"Twamley","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0370","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.schres.2007.10.030","article-title":"Neuropsychological substrates and everyday functioning implications of prospective memory impairment in schizophrenia","volume":"106","author":"Twamley","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2015.08.010_bb0375","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1017\/S0033291799002627","article-title":"Social disability in schizophrenia: its development and prediction over 15years in incidence cohorts in six European centres","volume":"30","author":"Wiersma","year":"2000","journal-title":"Psychol. Med."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584615300300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584615300300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T18:47:39Z","timestamp":1653072459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584615300300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":75,"alternative-id":["S0278584615300300"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2015.08.010","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2015.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}